Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer

The introduction of enzalutamide and abiraterone has led to improvement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short period in many patients. In the present study...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Res
Главные авторы: Liu, Chengfei, Lou, Wei, Zhu, Yezi, Yang, Joy C., Nadiminty, Nagalakshmi, Gaikwad, Nilesh W., Evans, Christopher P., Gao, Allen C.
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4383695/
https://ncbi.nlm.nih.gov/pubmed/25649766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-3080
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы